10 Small-Cap Cancer Tickers: What They Promised, What They Delivered

Before ASCO 2026 began, investors, analysts, and biotech watchers flagged their top tickers heading into ASCO 2026, the list spanned rare cancers, intractable indications, and scientific questions the field had been wrestling with for years. RAS inhibition. Notch signaling. Non-classical EGFR mutations. Checkpoint resistance. Each program carried a specific question: had the science been translated into a result patients and oncologists could act on?

Now that the meeting is over and the data is public, a clearer picture has emerged of which companies met expectations, which exceeded them, and which still have key questions to answer. While the results varied, several common themes emerged: long-standing scientific challenges are beginning to yield, biomarker-driven drug development continues to gain momentum, and a handful of small-cap biotechs may have significantly altered their competitive position heading into the next phase of clinical and regulatory development.

1. IDEAYA Biosciences (IDYA) — The First Drug That Works in Uveal Melanoma

Uveal melanoma — a rare eye cancer driven almost entirely by GNAQ/GNA11 mutations — kills most patients within a year of metastasis and, until now, had no approved systemic therapy for the majority of cases. Checkpoint immunotherapy barely moves the needle because the tumor microenvironment is profoundly immunosuppressive. IDEAYA and partner Servier targeted the downstream PKC signaling pathway instead, and the phase 2/3 OptimUM-02 trial landed cleanly. Darovasertib plus crizotinib met its primary endpoint: median PFS of 6.9 versus 3.1 months (HR 0.42; P<0.0001), an ORR of 37.1% versus 5.8%, and five complete responses in the darovasertib arm. Treatment discontinuation due to adverse events was 2.5% versus 19% for investigator’s choice.

Why it matters: this is the first randomized trial to demonstrate a significant PFS benefit in this setting. The FDA accepted the NDA for Real-Time Oncology Review, with full NDA filing expected H2 2026. Beyond this approval, IDEAYA is building across the entire uveal melanoma disease continuum: three registrational phase 3 trials are active or planned (OptimUM-02 for metastatic disease, OptimUM-10 for neoadjuvant, and OptimUM-11 for adjuvant primary disease). Data in HLA-A*02:01-positive patients — a label expansion population — are expected H2 2026. A company with cash runway to 2030 and U.S. commercial rights is now one approval away from becoming the standard of care in a disease that previously had none. 

2. Karyopharm Therapeutics (KPTI) — Doubling Spleen Response in Myelofibrosis

Myelofibrosis is a bone marrow cancer where JAK inhibitors like ruxolitinib are the current standard — but leave most patients with residual disease and a persistent transformation risk. The phase 3 SENTRY trial (NCT04562389), published simultaneously in the Journal of Clinical Oncology, asked whether adding selinexor — a nuclear export inhibitor targeting XPO1 — could improve on ruxolitinib alone. It did. The selinexor combination achieved an SVR35 rate (spleen volume reduction ≥35% at week 24) of 50% versus 28% — nearly a doubling. The overall survival signal cut death risk by more than 50%. Treatment-related deaths were actually lower in the combination arm (0.9% versus 2.6%), despite higher Grade 3+ adverse events (70% versus 50%), which were predominantly hematologic.

Why it matters: the treatment standard for myelofibrosis has stagnated for years and XPO1 inhibition has struggled to find a clear clinical niche. A near-doubling of spleen response in a disease where patients have limited options is a meaningful step forward. Karyopharm is pursuing regulatory submissions and potential compendia inclusion in H2 2026. If approved, selinexor would move from a niche approved indication (relapsed/refractory myeloma) into a front-line myelofibrosis combination — a significantly larger patient population with a much cleaner commercial profile.

3. Revolution Medicines (RVMD) — The Result That Ended “Undruggable”

This was the defining result of the season — covered in depth in our companion coverage. The phase 3 RASolute 302 trial showed daraxonrasib, an oral RAS(ON) multi-selective inhibitor, reduced mortality risk by 60% versus chemotherapy in previously treated metastatic pancreatic cancer (OS HR 0.40; P<0.0001). Median overall survival doubled: 13.2 versus 6.7 months. The audience gave a standing ovation. The New England Journal of Medicine published the data simultaneously. FDA submission is planned under a Commissioner’s National Priority Voucher, and expanded access is now authorized by the FDA for eligible patients who cannot wait.

Why it matters: pancreatic cancer kills over 466,000 people annually worldwide and has a five-year metastatic survival rate below 3%. The era of RAS being “undruggable” ended here. Revolution Medicines now has three additional registrational programs running — first-line metastatic PDAC (RASolute 303), adjuvant PDAC (RASolute 304), and previously treated NSCLC (RASolve 301) — plus a separate G12D-selective inhibitor (zoldonrasib) with FDA Breakthrough Therapy Designation in lung cancer. The company’s $2.2 billion in raised capital gives it the runway to execute all of them.

4. Cogent Biosciences (COGT) — First Drug to Beat Sunitinib in GIST, Ever

Gastrointestinal stromal tumors (GIST) were transformed by imatinib. Sunitinib has been the standard second-line therapy for 20 years after imatinib resistance develops. In those 20 years, no treatment had ever beaten sunitinib in a randomized trial in this setting. Cogent’s phase 3 PEAK trial changed that. Bezuclastinib plus sunitinib reduced disease progression or death risk by 50% versus sunitinib alone (HR 0.50; P<0.0001). Median PFS was 16.5 versus 9.2 months. ORR was 46% versus 26%. Mean treatment duration reached 21.4 months. The benefit held across both primary and secondary KIT mutations — critical in a disease defined by resistance driven by secondary mutation heterogeneity.

Why it matters: two decades of failed trials in second-line GIST ended here. The FDA has granted Priority Review with a PDUFA date of November 30, 2026, and no advisory committee is planned. Beyond GIST, bezuclastinib already has a separate NDA accepted for non-advanced systemic mastocytosis (PDUFA December 30, 2026) and an AdvSM NDA submitted — meaning Cogent could enter 2027 as a three-indication commercial company. A new 40-patient extension cohort is now enrolling first-line GIST patients with KIT exon 9 mutations, building the evidence base for an even earlier line of treatment.

5. Black Diamond Therapeutics (BDTX) — 86% Brain Response in an Unmet NSCLC Population

Non-classical EGFR mutations affect roughly 10–15% of EGFR-mutant NSCLC patients, resist current TKIs, progress into the central nervous system, and have had no dedicated approved therapy. Black Diamond’s phase 2 data for silevertinib in treatment-naive patients delivered an ORR of 60% — including 25 confirmed partial responses and one complete response. The CNS ORR was 86% per RANO-BM criteria, and median PFS reached 15.2 months, far exceeding historical benchmarks in this mutation class. As of data cutoff, 29 of 43 patients remained on treatment.

Why it matters: CNS penetration is the differentiating data point here. Most EGFR inhibitors fail in the brain; an 86% intracranial response rate in a population with no current dedicated option is the kind of number that draws regulatory attention and defines competitive positioning. Black Diamond is also presenting silevertinib data in previously treated patients and C797S resistance mutations, and has launched a phase 2 GBM trial in EGFRvIII-positive glioblastoma — extending the program beyond NSCLC into a second high-unmet-need indication. The pivotal trial design for non-classical EGFR NSCLC is the immediate next step, and the existing phase 2 data provide a strong basis for it.

6. Immuneering (IMRX) — 17.3 Months in First-Line Pancreatic Cancer

MEK inhibition has repeatedly failed in oncology due to resistance mechanisms and toxicity. Immuneering’s atebimetinib uses a “deep cyclic” mechanism designed to address both failure modes. The phase 2a oral presentation covered 55 first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel. Median OS was 17.3 months — compared with 8.5 months in the pivotal MPACT study of standard-of-care gemcitabine/nab-paclitaxel. The only Grade 3+ treatment-related adverse events exceeding 10% were anemia (16%) and neutropenia (18%), both chemotherapy-driven rather than drug-related.

Why it matters: 17.3 months as a first-line median OS in pancreatic cancer is a compelling single-arm signal — particularly against a historical baseline of 8.5 months. The pivotal phase 3 MAPKeeper 301 trial is now enrolling, with first patient dosing expected mid-2026, and a phase 2 arm in NSCLC combining atebimetinib with anti-PD-1 is planned for H2 2026. The context matters here: with Revolution Medicines’ daraxonrasib redefining what second-line PDAC survival can look like, a strong first-line signal becomes even more strategically significant. If MAPKeeper 301 holds, atebimetinib could occupy a distinct earlier-line position in pancreatic cancer with a tolerable profile that complements rather than competes with RAS-targeted agents.

7. Immunome (IMNM) — The First Approved Therapy for Desmoid Tumors, If the FDA Agrees

Desmoid tumors are rare, locally aggressive soft tissue tumors with no distant metastases but significant morbidity — chronic pain, compression of vital structures, unpredictable behavior. There is no approved systemic therapy. Notch signaling drives their growth; varegacestat (formerly AL102) is an oral gamma secretase inhibitor that blocks that pathway. Phase 3 RINGSIDE enrolled 156 patients — the largest randomized desmoid tumor study ever — and met its primary endpoint and all key secondary endpoints. Varegacestat achieved a 56% objective response rate, an 84% reduction in progression risk, and statistically significant pain improvement as early as week 4. Safety showed predominantly Grade 1–2 events (95%), though dose reductions were common and ovarian toxicity in premenopausal women requires monitoring.

Why it matters: no approved therapy for desmoid tumors exists anywhere. Immunome submitted the NDA to the FDA in April 2026, with an EMA Marketing Authorization Application planned by end of 2026. Regulatory risk is real — the dose reduction rate and ovarian toxicity signal will require scrutiny — but the clinical case for a patient population with no alternatives is strong. Approval would also represent the first clinical validation of Notch inhibition as a therapeutic strategy, potentially opening a new mechanistic class of oncology drugs.

8. Agenus (AGEN) — Making Immunotherapy Work Where It Hasn’t Before

Botensilimab is a next-generation CTLA-4 antibody engineered for enhanced Fc-mediated effector function — designed to generate stronger immune activation than standard ipilimumab, including in immunologically “cold” tumors. The phase 2 data in advanced cutaneous melanoma — specifically patients refractory or resistant to anti-PD-(L)1, with or without prior CTLA-4 inhibition — showed durable responses and meaningful survival in a population with few remaining options after checkpoint failure.

Why it matters: the data add another tumor type to the multi-cancer evidence base for BOT+BAL, but the pivotal readout to watch is BATTMAN (NCT07152821) — a global phase 3 trial in refractory MSS/pMMR metastatic colorectal cancer, a population historically considered non-responsive to immunotherapy. First patient enrolled in April 2026 across more than 100 sites in Canada, France, Australia, and New Zealand. Phase 2 data in this MSS colorectal population previously showed a 42% two-year survival rate and a 20.9-month median OS — numbers that significantly outperform chemotherapy’s historical 10–14 months. If BATTMAN confirms those signals, botensilimab becomes the first immunotherapy to meaningfully move the needle in one of oncology’s most resistant tumor types.

9. Cardiff Oncology (CRDF) — Early Evidence in KRAS-Mutant Colorectal Cancer

Onvansertib is a PLK1 (polo-like kinase 1) inhibitor — a cell-cycle target that has attracted oncology interest for decades without establishing a clear clinical footprint. Cardiff is testing it in KRAS-mutant metastatic colorectal cancer, a population underserved by EGFR-targeted agents and current immunotherapy. The updated phase 2 poster presented data from the onvansertib plus chemotherapy and bevacizumab combination in KRAS-mutant mCRC, adding incremental evidence for PLK1 inhibition in a biomarker-defined subgroup.

Why it matters: this is the most early-stage result on this list — a phase 2 poster rather than a phase 3 readout — and it does not yet answer whether onvansertib can deliver the durable signal needed to justify a randomized phase 3. The KRAS-mutant CRC rationale is scientifically coherent — these patients cannot benefit from EGFR inhibitors and have limited immunotherapy options — and PLK1 inhibition in a biomarker-selected population is an underexplored mechanism. Cardiff’s competitive position is fragile relative to the other names here, but its program occupies a real gap in an indication that larger companies are now racing to address via different mechanisms (RAS inhibitors, CEA-directed therapies). The question is whether Cardiff can generate the phase 3-enabling data before that window closes.

10. Ascentage Pharma (AAPG) — One Drug, Three Indications, Three Phase 3 Trials Running

Ascentage presented a dense, multi-indication data package for olverembatinib — one drug, multiple settings. In second-line CML-CP, updated data showed complete cytogenetic response of 91.3% and major molecular response of 60.9% at cycle 24 — deep, durable results in a TKI-resistant population. Then, in CML-LBP and Ph+ ALL in combination with blinatumomab, phase 1b data showed a 91% CR/CRi rate, 67% BCR::ABL1 PCR negativity, and 80% MRD negativity. Further, in SDH-deficient GIST, early data showed median PFS of 25.7 months with mechanistic evidence that olverembatinib targets the p38-CD36 fatty acid pathway — the first time this biology has been shown in this tumor type.

Why it matters: Ascentage’s one-drug, three-disease strategy is unusual and the multi-indication data package reinforces the underlying biology’s breadth. Three global phase 3 registrational trials are running: POLARIS-1 (Ph+ ALL), POLARIS-2 (CML-CP), and POLARIS-3 (SDH-deficient GIST) — two cleared by both FDA and EMA. Takeda holds an exclusive option for global rights outside Greater China, meaning a major partnership activation could follow positive phase 3 readouts. For a company operating across hematologic and solid tumor indications simultaneously, the commercial optionality here is substantial if the registrational trials deliver.

The Scorecard: Who Delivered, Who Is Building, and Who Still Has Questions

Not every result on this list carries equal weight. The more meaningful distinction is between companies with regulatory paths already underway and those still building toward pivotal development.

Six companies are on clear regulatory or late-stage trajectories:

• IDEAYA Biosciences (IDYA): NDA under FDA Real-Time Oncology Review, with filing completion expected in H2 2026.
• Karyopharm Therapeutics (KPTI): Regulatory submissions planned following positive Phase 3 SENTRY data.
• Revolution Medicines (RVMD): FDA submission planned for daraxonrasib, expanded access authorized, and multiple Phase 3 programs underway.
• Cogent Biosciences (COGT): FDA Priority Review secured for bezuclastinib, with a PDUFA date of November 30, 2026.
• Immunome (IMNM): NDA filed for varegacestat in April 2026, with a European submission planned by year-end.
• Black Diamond Therapeutics (BDTX): Pivotal development planning underway following encouraging Phase 2 data in non-classical EGFR-mutant NSCLC.

Two companies have generated promising data with clear late-stage paths ahead:

• Immuneering (IMRX): Strong Phase 2 pancreatic cancer data supporting advancement into Phase 3.
• Ascentage Pharma (AAPG): Broad multi-indication data package backed by three ongoing registrational Phase 3 studies.

Two others remain earlier in their development journey:

• Agenus (AGEN): Building evidence for botensilimab and balstilimab, with the Phase 3 BATTMAN study as its key catalyst.
• Cardiff Oncology (CRDF): Continuing to advance onvansertib in KRAS-mutant colorectal cancer, though pivotal development remains further out.

The broader takeaway is that the strongest results came from diseases where progress had stalled for decades. Revolution Medicines (RVMD) delivered one of the most significant advances reported in previously treated pancreatic cancer, while Cogent Biosciences (COGT) became the first company to outperform sunitinib in a randomized study of imatinib-resistant GIST. Across the watchlist, the story was not incremental improvement—it was long-standing scientific challenges finally beginning to yield, with several small-cap biotechs now emerging as serious contenders in their respective fields.

Author

Bernice Lottering